Company intelligence
Samsung Biologics
Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.
About Samsung Biologics
Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
Verified activity
Signals from Samsung Biologics
7 published signals
Research & Knowledge
Samsung Biologics published a video explaining how selective intensification using N-1 perfusion enhances fed-batch productivity, achieving higher seeding density, VCD, and protein output while maintaining fed-batch.
Reported by Samsung Biologics
Presence & Recognition
Samsung Biologics is hosting an upcoming webinar featuring Director of Organoids Technology SEAHEE KIM, Ph.D., to discuss patient-derived tumor organoids and ADC activity in translational research.
Reported by Samsung Biologics
Presence & Recognition
Samsung Biologics announced that CPHI is around the corner, allowing customers to connect and learn more about capability and capacity expansions.
Reported by John Gagliardi
Operations & Supply
Samsung Biologics combines 845,000 L of world-class capacity with dedicated bioconjugation services to enable true end-to-end delivery from ADCs to next-generation modalities.
Reported by Samsung Biologics
Presence & Recognition
Samsung Biologics hosted an on-demand webinar featuring Jeffrey Mason, VP, Head of US Sales, discussing standardized operations, digitalization, and multi-plant sourcing for scalable manufacturing and supply flexibility.
Reported by Samsung Biologics
Products & Services
Samsung Biologics released a promoter-optimized mini helper plasmid that boosts AAV manufacturing yield.
Reported by Samsung Biologics
Research & Knowledge
Samsung Biologics published a whitepaper exploring how the company combines LC-MS-based host-cell protein profiling with a targeted lipase activity assay to assess lipase-related stability concerns.
Reported by Samsung Biologics